Literature DB >> 12928585

4-aminopyridine transiently increases intraocular pressure in rabbits.

Robin R Socci1, Eugenia Chu, Mohamed A Bayorh, Teh-Ching Chu.   

Abstract

The purpose of this study is to determine the mechanisms of action involved in the ocular hypertension induced by 4-aminopyridine (4-AP), a voltage-dependent potassium (K+) channel blocker, in rabbits. Topical application of 4-AP elevated intraocular pressure (IOP). This action caused increases in the aqueous flow rate as well as aqueous levels of protein and norepinephrine. In isolated iris-ciliary body preparations, 4-AP (0.01, 0.1, 1 mmol/l) caused dose-related increases in field-stimulated norepinephrine release by 43, 222 and 243%, respectively. Taken together, the IOP-elevating effect evoked by 4-AP was associated with enhancement of aqueous norepinephrine levels and norepinephrine release from sympathetic nerves of the iris-ciliary body. These results demonstrate that the 4-AP-sensitive K+ channels in sympathetic nerves and the ciliary epithelium are the potential sites of action of the 4-AP-induced ocular hypertension. Copyright 2003 S. Karger AG, Basel

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2003        PMID: 12928585     DOI: 10.1159/000072364

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  2 in total

1.  Digoxin derivatives with selectivity for the α2β3 isoform of Na,K-ATPase potently reduce intraocular pressure.

Authors:  Adriana Katz; Daniel M Tal; Dan Heller; Michael Habeck; Efrat Ben Zeev; Bilal Rabah; Yaniv Bar Kana; Arie L Marcovich; Steven J D Karlish
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-19       Impact factor: 11.205

2.  Digoxin derivatives with enhanced selectivity for the α2 isoform of Na,K-ATPase: effects on intraocular pressure in rabbits.

Authors:  Adriana Katz; Daniel M Tal; Dan Heller; Haim Haviv; Bilal Rabah; Yaniv Barkana; Arie L Marcovich; Steven J D Karlish
Journal:  J Biol Chem       Date:  2014-06-10       Impact factor: 5.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.